Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 5/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.41 |
| ▸ | FLT3 | P36888 | 4/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA5A | P35218 | 3/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370675 | 1.00 | RXRA (0.41) | RXRAGRIN1GRIN2BFLT3GSK3B | |
| SCHEMBL17666284 | 0.73 | LRRK2 (0.50) | RXRAGRIN1GRIN2BFLT3GSK3B | |
| SCHEMBL12722348 | 0.73 | SIGMAR1 (0.44) | RXRAGRIN1GRIN2BFLT3CA1 | |
| SCHEMBL12420392 | 0.72 | BCHE (0.52) | FLT3GSK3BCA1CA2CA12 | |
| SCHEMBL31158277 | 0.70 | FLT3 (0.58) | RXRAGRIN1GRIN2BFLT3GSK3B | |
| SCHEMBL17666321 | 0.70 | RXRA (0.42) | RXRAGRIN1GRIN2BFLT3GSK3B | |
| SCHEMBL18456211 | 0.70 | BCHE (0.44) | RXRAGRIN1GRIN2BFLT3GSK3B | |
| SCHEMBL17666313 | 0.70 | RXRA (0.40) | RXRAGRIN1GRIN2BFLT3GSK3B | |
| SCHEMBL17666326 | 0.70 | RXRA (0.51) | RXRAGRIN1GRIN2BAMY1A | |
| SCHEMBL27007952 | 0.69 | FLT3 (0.42) | FLT3GSK3BCA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247558-B2 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-2247558-B2 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-2247558-B1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2022-02-02 | — | — | EP | disclosed |
| EP-2247558-B1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2022-02-02 | — | — | EP | disclosed |
| EP-2599763-A1 | Novel imaging agents for detecting neurological dysfunction | Siemens Molecular Imaging, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| EP-2599763-A1 | Novel imaging agents for detecting neurological dysfunction | Siemens Molecular Imaging, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-8318132-B2 | Imaging agents for detecting neurological dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318132-B2 | Imaging agents for detecting neurological dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318132-B2 | Imaging agents for detecting neurological dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110091382-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTION USA, INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110091382-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTION USA, INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110091382-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTION USA, INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2009102498-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110091382-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | FABP7, TSPO, SLC18A3 | RXRA 3633/4885GRIN1 775/4885GRIN2B 644/4885 |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | FABP7, SLC18A3, TSPO | RXRA 3680/4885GRIN1 696/4885GRIN2B 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.